Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
February 14, 2025 09:05 ET
|
Longeveron
Longeveron to present at the Emerging Growth Virtual Conference taking place February 18-19, 2025.
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
February 03, 2025 06:22 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Axiom Brain Health and Global Alzheimer’s Platform Foundation Celebrate the Next Chapter in Innovative Research in Tampa
January 24, 2025 10:29 ET
|
Global Alzheimer’s Platform Foundation®
Tampa, Fla., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Axiom Brain Health (Axiom) and the Global Alzheimer’s Platform Foundation® (GAP) celebrated the next chapter in neurodegenerative research at the...
Beckman Coulter Diagnostics Joins the Transformative Bio-Hermes-002 Study as New Partner
January 23, 2025 09:01 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Jan. 23, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002...
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
January 07, 2025 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
December 30, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to...
Longeveron to Present at Biotech Showcase 2025
December 18, 2024 09:10 ET
|
Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
December 17, 2024 09:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study
December 09, 2024 10:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This...
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
December 02, 2024 09:05 ET
|
Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.